Adage Capital Partners
IMVT icon

Adage Capital Partners’s Immunovant IMVT Stock Holding History

Adage Capital Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3M Sell
413,000
-450,000
-52% -$11.7M 0.02% 678
2025
Q4 		$21.9M Buy
863,000
+519,400
+151% +$11.6M 0.03% 456
2025
Q3 		$5.54M Sell
343,600
-120,000
-26% -$1.94M 0.01% 723
2025
Q2 		$7.42M Buy
463,600
+442,400
+2,087% +$6.69M 0.01% 665
2025
Q1 		$362K Sell
21,200
-278,800
-93% -$5.83M ﹤0.01% 817
2024
Q4 		$7.43M Hold
300,000
– – 0.01% 664
2024
Q3 		$8.55M Sell
300,000
-120,000
-29% -$3.54M 0.02% 640
2024
Q2 		$11.1M Buy
420,000
+320,000
+320% +$9.1M 0.02% 579
2024
Q1 		$3.23M Sell
100,000
-1,231,780
-92% -$44.9M 0.01% 741
2023
Q4 		$56.1M Buy
1,331,780
+897,280
+207% +$33M 0.12% 187
2023
Q3 		$16.7M Buy
+434,500
New +$9.82M 0.04% 441
2021
Q1 		– Sell
-1,400,851
Closed -$64.7M – 985
2020
Q4 		$64.7M Buy
1,400,851
+95,851
+7% +$4.43M 0.14% 162
2020
Q3 		$45.9M Sell
1,305,000
-1,061,062
-45% -$31.9M 0.12% 191
2020
Q2 		$57.6M Buy
2,366,062
+1,346,062
+132% +$28.8M 0.15% 160
2020
Q1 		$15.9M Hold
1,020,000
– – 0.05% 375
2019
Q4 		$16.2M Buy
+1,020,000
New +$11.4M 0.04% 423

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners's IMVT Position: Q1 2026 in Review

Adage Capital Partners reduced its Immunovant (IMVT) stake by 52% in Q1 2026, selling an estimated $11.7M and leaving 413,000 shares worth $10.3M. The position accounts for 0.02% of the portfolio, ranked #678.

Adage Capital Partners first reported a position in IMVT in Q4 2019 and has held it in 16 quarters since. The position peaked at $64.7M in Q4 2020. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Adage Capital Partners held 413,000 shares of Immunovant worth $10.3M as of Q1 2026.
  • Adage Capital Partners sold 450,000 Immunovant shares in Q1 2026, an estimated $11.7M.
  • Immunovant made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #678 holding.
  • Adage Capital Partners first reported a position in Immunovant in Q4 2019 and has held it in 16 quarters since.
  • Adage Capital Partners's Immunovant position peaked at $64.7M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.